alexa Expression Of D2-40 In Benign And Malignant Breast Lesions And Study The Correlation Between Lymphovascular Density And Other Prognostic Factors Of Breast Cancer
ISSN: 2572-4118

Breast Cancer: Current Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th World Congress on Breast Cancer
May 08-10, 2017 Singapore

Hala Abdeldayem Mouhamed and Afaf Taha Ibrahiem
Suez Canal University, Egypt
Mansoura University, Egypt
Posters & Accepted Abstracts: Breast Can Curr Res
DOI: 10.4172/2572-4118-C1-003
Abstract
Background: D2-40 is a mouse monoclonal antibody specific for human podoplanin and has been used in identifying lymphovascular invasion (LVI) of tumors also its expression has been used as a marker for myoepithelial cells (MEC) of breast. Lymphangiogenesis, assessed as lymphovascular density (LVD), is the initial step of generalized tumor lymphovascular invasion (LVI). It also involves VEGF-C as the most important protein family. Lymphangiogenesis among breast cancer cases correlates with several clinicopathological factors are important to determine prognosis and treatment strategies, but results have been controversial and require clarification. Aim: The aim of this work is to explore the expression of D2-40 as a marker for myoepithelial cells (MECs) of the breast lesions, to investigate the clinicopathological significance of VEGF-C, D2-40 expression and lymphovascular density (LVD) in breast cancer patients. Methods: Sections from 88 paraffin-embedded archival specimens of breast lesions were selected to include benign breast lesions as fibrocystic changes of the breast and ductal hyperplasia (15 cases) and invasive breast cancer (73 cases). Immunohistochemistry (IHC) for D2-40, calponin and VEFG-C were performed and IHC staining results and the associations of intratumoral and peritumoral LVD were correlated with clinicopathologi¬cal features and prognosis were assessed. Results: D2-40 highlighted the MECs of benign breast lesions beside its identified lymphatic vessels and LVI in breast carcinomas. VEGF-C expression was significantly higher in invasive breast cancer than benign breast lesions (p<0.01). VEGF-C (p<0.001) expression was significantly associated with peritumoral LVD, but not intratumoral LVD. VEGF-C expression, peritumoral LVD and LVI were significantly associated with lymph node metastasis (p=0.025, p=0.006 and p=0.017, respectively). Moreover, peritumoral LVD was an independent risk factor for axillary lymph node metastasis, disease-free survival in multivariate analysis. Conclusions: Our results show that D2-40 is a reliable marker highlights MECs in benign breast lesions beside it is a useful tool for identification of LVI in breast carcinomas which is reflecting a potential for lymphatic metastatic spread and possible poor prognosis. Our study also demonstrated that high expression of VEGF-C in invasive breast carcinoma may induce lymphangiogenesis in the peritumoral area. Peritumoral LVD appeared to be a potential independent prognostic factor in breast cancer patients.
Biography

Email: hala.abdeldayem@yahoo.com

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsonline.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsonline.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsonline.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsonline.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsonline.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsonline.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsonline.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsonline.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsonline.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsonline.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsonline.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsonline.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsonline.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsonline.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsonline.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsonline.com

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords